BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 18048835)

  • 1. Reversibility of trastuzumab cardiotoxicity: is the concept alive and well?
    Ewer MS; Tan-Chiu E
    J Clin Oncol; 2007 Dec; 25(34):5532-3; author reply 5533-4. PubMed ID: 18048835
    [No Abstract]   [Full Text] [Related]  

  • 2. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?
    Morris PG; Hudis CA
    J Clin Oncol; 2010 Jul; 28(21):3407-10. PubMed ID: 20530269
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
    Popat S; Smith IE
    Nat Clin Pract Oncol; 2008 Jun; 5(6):324-35. PubMed ID: 18364726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
    Gianni L; Salvatorelli E; Minotti G
    Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
    Telli ML; Hunt SA; Carlson RW; Guardino AE
    J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
    Castrellon AB; Glück S
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anthracyclines and trastuzumab; getting to the heart of the matter: when getting to the heart is the matter.
    Morris PG; Hudis CA
    Breast Cancer Res Treat; 2011 Jun; 127(2):585-6. PubMed ID: 18791822
    [No Abstract]   [Full Text] [Related]  

  • 8. Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction.
    Ewer MS; Ewer SM
    J Clin Oncol; 2010 Sep; 28(25):3901-4. PubMed ID: 20679626
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients.
    Perik PJ; de Korte MA; van Veldhuisen DJ; Gietema JA; Sleijfer DT; de Vries EG
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1763-71. PubMed ID: 18062750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab beyond progression: is the risk of cardiac toxicity really not increased?
    Morabito A; Piccirillo MC; De Maio E; Di Maio M; Perrone F
    J Clin Oncol; 2009 Sep; 27(27):e123; author reply e124-5. PubMed ID: 19687322
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemotherapy-induced cardiotoxicity in women.
    Dempsey KS
    Crit Care Nurs Clin North Am; 2008 Sep; 20(3):343-50. PubMed ID: 18644518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controversies in the use of adjuvant trastuzumab (Herceptin).
    Chowdhury S; Pickering L; Ellis P
    J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac risks in multimodal breast cancer treatment.
    Budach W
    Strahlenther Onkol; 2007 Dec; 183 Spec No 2():9-10. PubMed ID: 18166997
    [No Abstract]   [Full Text] [Related]  

  • 14. Trastuzumab-associated cardiotoxicity.
    Keefe DL
    Cancer; 2002 Oct; 95(7):1592-600. PubMed ID: 12237930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
    Rowan K
    J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
    [No Abstract]   [Full Text] [Related]  

  • 16. Trastuzumab versus lapatinib: the cardiac side of the story.
    Azim H; Azim HA; Escudier B
    Cancer Treat Rev; 2009 Nov; 35(7):633-8. PubMed ID: 19640652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Learn to assess for and manage trastuzumab-induced cardiotoxicity.
    Becze E
    ONS Connect; 2009 Dec; 24(12):12-3. PubMed ID: 20039567
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical cardiac tolerability of trastuzumab.
    Perez EA; Rodeheffer R
    J Clin Oncol; 2004 Jan; 22(2):322-9. PubMed ID: 14722042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herceptin and the heart--a molecular modifier of cardiac failure.
    Chien KR
    N Engl J Med; 2006 Feb; 354(8):789-90. PubMed ID: 16495390
    [No Abstract]   [Full Text] [Related]  

  • 20. Trastuzumab-induced cardiotoxicity: heart failure at the crossroads.
    Sengupta PP; Northfelt DW; Gentile F; Zamorano JL; Khandheria BK
    Mayo Clin Proc; 2008 Feb; 83(2):197-203. PubMed ID: 18241629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.